(Q30413695)

21 June 2017

title

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion (English)

1 reference

21 June 2017

1 reference

Nathalie Garçon

1

1 reference

21 June 2017

David W Vaughn

series ordinal

2

1 reference

21 June 2017

Arnaud M Didierlaurent

series ordinal

3

1 reference

21 June 2017

publication date

1 March 2012

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

11

1 reference

21 June 2017

issue

3

1 reference

21 June 2017

page(s)

349-366

1 reference

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Vitamin E, antioxidant and nothing more

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Regulation of gene expression by alpha-tocopherol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Modulation of signal transduction by vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Vitamin E in viral inactivated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Human cholesterol metabolism and therapeutic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Squalene: A natural triterpene for use in disease management and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Induction of immunity to human immunodeficiency virus type-1 by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

H5N1 influenza--continuing evolution and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Correlates of protection: novel generations of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and protective efficacy of influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Antibody induction by influenza vaccines in the elderly: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immune responses to influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 month

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Response to a monovalent 2009 influenza A (H1N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

2009 Pandemic influenza A (H1N1) deaths among children--United States, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

NF-kappaB and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.192

21 January 2018

Identifiers

DOI

10.1586/ERV.11.192

1 reference

21 June 2017

1 reference